全文获取类型
收费全文 | 393527篇 |
免费 | 37433篇 |
国内免费 | 27392篇 |
专业分类
耳鼻咽喉 | 3145篇 |
儿科学 | 5123篇 |
妇产科学 | 4336篇 |
基础医学 | 42698篇 |
口腔科学 | 6506篇 |
临床医学 | 55163篇 |
内科学 | 52746篇 |
皮肤病学 | 4322篇 |
神经病学 | 18989篇 |
特种医学 | 14471篇 |
外国民族医学 | 225篇 |
外科学 | 34999篇 |
综合类 | 74867篇 |
现状与发展 | 90篇 |
一般理论 | 31篇 |
预防医学 | 29510篇 |
眼科学 | 10943篇 |
药学 | 43029篇 |
462篇 | |
中国医学 | 26065篇 |
肿瘤学 | 30632篇 |
出版年
2024年 | 1379篇 |
2023年 | 5742篇 |
2022年 | 15060篇 |
2021年 | 19191篇 |
2020年 | 15171篇 |
2019年 | 12256篇 |
2018年 | 12709篇 |
2017年 | 12317篇 |
2016年 | 11273篇 |
2015年 | 17666篇 |
2014年 | 22031篇 |
2013年 | 20249篇 |
2012年 | 29986篇 |
2011年 | 33504篇 |
2010年 | 22875篇 |
2009年 | 18582篇 |
2008年 | 22578篇 |
2007年 | 22293篇 |
2006年 | 21184篇 |
2005年 | 20174篇 |
2004年 | 13472篇 |
2003年 | 13076篇 |
2002年 | 10849篇 |
2001年 | 9213篇 |
2000年 | 8743篇 |
1999年 | 8730篇 |
1998年 | 5475篇 |
1997年 | 5248篇 |
1996年 | 4096篇 |
1995年 | 3840篇 |
1994年 | 3244篇 |
1993年 | 2072篇 |
1992年 | 2486篇 |
1991年 | 2180篇 |
1990年 | 1837篇 |
1989年 | 1588篇 |
1988年 | 1313篇 |
1987年 | 1207篇 |
1986年 | 985篇 |
1985年 | 692篇 |
1984年 | 373篇 |
1983年 | 276篇 |
1982年 | 147篇 |
1981年 | 172篇 |
1980年 | 118篇 |
1979年 | 154篇 |
1978年 | 73篇 |
1977年 | 53篇 |
1974年 | 42篇 |
1972年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
Xia Li Wang Junni Xie Xishao Xiang Shilong Zhang Xiaohui Chen Jianghua Han Fei 《中华肾脏病杂志》2020,36(7):497-502
Objective To observe the clinical characteristics and prognosis of patients with rapidly progressive glomerulonephritis (RPGN) caused by lupus nephritis, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, or primary glomerulonephritis who were treated with peritoneal dialysis (PD) and then withdrew PD because of renal recovery. Methods Data of the above patients were retrospectively analyzed. The patients were diagnosed as RPGN and received PD therapy in Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University from February 2009 to August 2018. The patients were divided into early withdrawal group (PD time≤183 days, n=24) and late withdrawal group (PD time>183 day, n=24). The differences of clinical characteristics between the two groups were compared. The cumulative incidence of adverse events in both groups was analyzed using Kaplan-Meier curves. Cox proportional hazards model was used to analyze the risk factors influencing the prognosis of patients. Results Forty-eight RPGN patients were included. The median time of maintaining PD was 178(76, 378) days. Compared with the late withdrawal group, the patients in early withdrawal group had lower levels of urine volume, serum albumin and parathyroid hormone, and lower rates of gross hematuria and hypertension at the beginning of PD, and received higher rates of methylprednisolone impulse, combined immunosuppressive agents, and hemodialysis or continuous renal replacement therapy (all P<0.05). At the time of PD withdrawal, the levels of serum creatinine, serum calcium, serum albumin and parathyroid hormone in the early withdrawal group were significantly lower than those in the late withdrawal group (all P<0.05). The Kaplan-Meier curves showed that there was no significant difference in the cumulative survival of patients in both groups (log-rank test χ2=3.485, P=0.062). Cox regression analysis revealed serum creatinine≥209 μmol/L at the time of PD withdrawal was an independent risk factor for poor prognosis (HR=5.253,95%CI 1.757-15.702, P=0.003). Conclusions PD can be used for RPGN patients caused by lupus nephritis, ANCA-associated vasculitis and primary nephritis. Serum creatinine≥209 μmol/L at the time of PD withdrawal is an independent risk factor for poor prognosis. 相似文献
142.
四妙勇安汤由金银花、玄参、当归、甘草4味药物组成,为《古代经典名方目录(第一批)》中100个经典名方之一。经溯源发现,四妙勇安汤源于《石室秘录》,后由《古今图书集成·医部全录》《验方新编》等书引用。从古代文献记载来看均有方无名,"四妙勇安汤"之名,最早见于1956年《中医治疗动脉栓塞性坏疽症的成效》,是由当时记者吕民报道河北省释迦宝山用"四妙勇安汤"治疗当地的动脉栓塞性坏疽时冠名。四妙勇安汤从方药组成与剂量上看,从《石室秘录》开始即是"金银花三两,当归二两,生甘草一两,玄参三两",历代版本《方剂学》确定四妙勇安汤金银花、玄参、当归、甘草的比例就是3∶3∶2∶1。而查阅文献,释迦宝山临证所用的四妙勇安汤由"玄参132 g,当归99 g,银花66 g,甘草33 g"组成,金银花、玄参、当归、甘草的比例变成2∶4∶3∶1。从治疗时间上看,原方记载的7日愈或是10日愈,而释迦宝山将其用到了三四个月,甚至五六个月。研究认为,古籍中的四妙勇安汤,应该是用于疾病的初期,尽早发现和治疗;而释迦宝山修改过的剂量,是广泛用于脱骨疽的中后期,甚至出现坏疽的严重病情所使用的,因此服药时间长,剂量大。且四妙勇安汤临证不仅限于治疗脱骨疽,也用于大头疮等,现代该方的使用已经大为拓展。相关研究已证实四妙勇安汤具有抗炎、稳定斑块、降脂、保护血管、改善血液流变学、抗凝、抑制血栓形成和促纤溶等作用,后续应开展君臣佐使辨析,对其临床应用范围重新进行界定。 相似文献
143.
144.
145.
146.
147.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
148.
149.
150.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis
下载免费PDF全文
![点击此处可从《Transfusion medicine (Oxford, England)》网站下载免费的PDF全文](/ch/ext_images/free.gif)